Impilo divests leading haemostatic device developer and manufacturer Ferrosan Medical Devices to Danish consortium of long-term investors
Impilo AB (“Impilo”) and other minority investors, incl. Hans-Christian Bødker Jensen, have signed an agreement to divest the Danish medical devices company Ferrosan Medical Devices Group A/S (“FeMD”) to a consortium of Danish long-term investors consisting of Kirk Kapital, Lundbeckfonden and ATP (the “Consortium”).
Impilo invested in FeMD in 2017 and has together with the management team realised the vision of creating a world leading medical devices group with product innovation and improved health outcomes at the core of its business. During Impilo’s ownership, revenues and EBITDA have doubled, substantial efforts have been put into bolstering the product innovation pipeline and large investments have gone into expanding the capacity at the company’s manufacturing sites, creating more than 100 new jobs. Further, FeMD has taken important steps towards becoming a more sustainable medical device company by increasing transparency and setting clear targets for its commitments to the environment, employees and patients.
Read moreNews
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.